All In Biotech

Drug Trial Radar · NCT02494986

A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies

An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jul 6, 2015

Primary completion

Aug 18, 2026

Study completion Aug 18, 2026

Sponsor

Lead sponsor
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 13, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 0 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.

Conditions

  • Human Immunodeficiency Virus Type 1

Interventions

  • RilpivirineDrug

    Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) related to rilpivirine (RPV)Time frame: Up to 32 Days from the last dose administered (Approximately 16 years)
  2. Number of Participants with AEs Leading to DiscontinuationTime frame: Up to 32 Days from the last dose administered (Approximately 16 years)
  3. Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 32 Days from the last dose administered (Approximately 16 years)
  4. Number of Participants with PregnanciesTime frame: Up to 32 Days from the last dose of administered (Approximately 16 years)
  5. Number or Participants with Grade 3/4 Rash Regardless of CausalityTime frame: Up to 32 Days from the last dose administered (Approximately 16 years)

Locations

8 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Porto, Portugal

  • Site not named

    Bloemfontein, South Africa

  • Site not named

    Dundee, South Africa

  • Site not named

    Esplugues de Llobregat, Spain

  • Site not named

    Bangkok, Thailand

  • Site not named

    Nonthaburi, Thailand

  • Site not named

    Entebbe, Uganda

  • Site not named

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.